Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy

Prenatal Diagnosis

Volumn 27, Issue 9, 2007, Pages 808-813

  Palomaki, Glenn E ^a,c   Neveux, Louis M ^a   Haddow, James E ^a   Wyatt, Philip ^b  

^a BROWN UNIVERSITY   (United States)

^b York Central Hospital Richmond Hill   (Canada)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Down syndrome; First trimester; Hyperglycosylated hCG (h hCG); Prenatal screening; Second trimester

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CLINICAL EXAMINATION; DISEASE MARKER; DOWN SYNDROME; FALSE POSITIVE RESULT; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GLYCOSYLATION; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; MEASUREMENT; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

ADULT; CHORIONIC GONADOTROPIN; COHORT STUDIES; DOWN SYNDROME; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 34548799145     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1778     Document Type: Article

References (26)

1. ACOG. 2004. ACOG Committee Opinion #296: First-trimester screening for fetal aneuploidy. Obstet Gynecol 104: 215-217.
2. Benn P, Wright D, Cuckle H. 2005. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 25: 645-652.
3. Brock DJ, Barron L, Holloway S, et al. 1990. First-trimester maternal serum biochemical indicators in Down syndrome. Prenat Diagn 10: 245-251.
4. Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. 1999. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. Clin Chem 45: 2109-2119.
5. Haddow JE, Palomaki GE, Knight GJ, et al. 1992. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 327: 588-593.
6. Haddow JE, Palomaki GE, Knight GJ, et al. 1998. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 338: 955-961.
7. Hyett JA, Noble PL, Snijders RJ, Montenegro N, Nicolaides KH. 1996. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 7: 239-244.
8. Palomaki GE, Lambert-Messerlian GM, Canick JA. 2007. A summary analysis of Down syndrome markers in the late first trimester. Adv Clin Chem 43: 177-210.
9. Palomaki GE, Steinort K, Knight GJ, Haddow JE. 2006. Comparing three screening strategies for combining first and second-trimester Down syndrome markers. Obstet Gynecol 107: 367-375.
10. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. 1997. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 176: 1046-1051.
11. Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Pandian R. 2004. Maternal serum invasive trophoblast antigen (hyperglycosylated hCG) as a screening marker for Down syndrome during the second trimester. Clin Chem 50: 1804-1808.
12. Palomaki GE, Knight GJ, Neveux LM, Pandian R, Haddow JE. 2005. Maternal serum invasive trophoblast antigen and first-trimester Down syndrome screening. Clin Chem 51: 1499-1504.
13. Pandian R, Lu J, Ossolinska-Plewnia J. 2003. Fully automated chemiluminometric assay for hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen). Clin Chem 49: 808-810.
14. Pandian R, Cole LA, Palomaki GE. 2004. Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening. Clin Chem 50: 1433-1435.
15. Szabo J, Gellen J. 1990. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 336: 1133.
16. Wald NJ, Watt HC, Hackshaw AK. 1999. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 341: 461-467.
17. Wald NJ, Rudnicka AR, Bestwick JP. 2006. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 26: 769-777.
18. Wald NJ, Cuckle HS, Densem JW, et al. 1988. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 297: 883-887.
19. Wald N, Stone R, Cuckle HS, et al. 1992. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. BMJ 305: 28.
20. Wald NJ, Rodeck C, Hackshaw AK, et al. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56-104.
21. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. 1996a. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 16: 143-153.
22. Wald NJ, George L, Smith D, Densem JW, Petterson K. 1996b. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International prenatal screening research group. Br J Obstet Gynaecol 103: 407-412.
23. Weinans MJ, Sancken U, Pandian R, et al. 2004. Invasive trophoblast antigen (Hyperglycosylated hCG) as a first-trimester serum marker for Down's syndrome. In Operationalization of First Trimester Maternal Serum Screening for Down's Syndrome, Weinans MJ (ed). Ponsen & Looyen BV: Wageningen; 111-122.
24. Weinans MJ, Sancken U, Pandian R, et al. 2005. Invasive trophoblast antigen (hyperglycosylated human chorionic gonadotropin) as a first-trimester serum marker for Down syndrome. Clin Chem 51: 1276-1279.
25. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. 2004. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24: 762-766.
26. Wright D, Bradbury I, Cuckle H, et al. 2006. Three-stage contingent screening for Down syndrome. Prenat Diagn 26: 528-534.